Digital twin for liver cancer: could computer simulations make radiation therapy more precise?

NCT ID NCT07315633

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is developing a computer-based planning tool to make transarterial radioembolization (TARE) more predictable for liver cancer patients. TARE delivers tiny radioactive beads directly to tumors, but results vary due to complex blood vessel patterns. Researchers will create digital models of each patient's liver arteries and simulate how the beads flow, aiming to help doctors choose the best catheter position and injection speed. The study involves 80 adults with liver cancer who are already scheduled for TARE, and uses their existing medical scans to build the models.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
radioactive microspheres (via transarterial radioembolization)
What this could lead to
If successful, this could lead to a digital tool that helps doctors plan more precise and effective liver cancer treatments, potentially improving outcomes and reducing damage to healthy tissue.
What could go wrong
This is an early-stage study focused on building and validating computer models, not testing a new treatment. The models may not perfectly predict real-world results, and any future benefits are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Ghent

    RECRUITING

    Ghent, 9000, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.